U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. ABECMA (idecabtagene vicleucel)
  1. Vaccines, Blood & Biologics

ABECMA (idecabtagene vicleucel)

STN: BLA 125736
Proper Name: idecabtagene vicleucel
Tradename: ABECMA
Manufacturer: Celgene Corporation, a Bristol-Myers Squibb Company
Indications:

  • Treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Product Information

Supporting Documents

 

Back to Top